BioSyent, Inc. is a specialty pharmaceutical company, which engages in the development of pharmaceutical and healthcare products. The company is headquartered in Mississauga, Ontario. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., sources, acquires or in-licenses and further develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary, operates the Company’s business marketing biologically and health friendly non-chemical insecticides. The Company’s products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Gelclair, Inofolic, Proktis-M, RepaGyn, and Tibella. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia. FeraMAX Pd Maintenance 45 is a chewable supplement with iron plus vitamin B12 and vitamin C for the prevention of iron deficiency anemia.
BioSyent Inc. 'in mevcut fiyatı $10.7 'dir, son işlem günde 0.46% arttırılmış etti.
BioSyent Inc. için ana iş temaları veya sektörler nelerdir?
BioSyent Inc. Pharmaceuticals endüstrisine ait ve sektör Health Care 'dir
BioSyent Inc. 'in piyasa değerlemesi nedir?
BioSyent Inc. 'in mevcut piyasa değerlemesi $120.5M 'dir
BioSyent Inc. al, sat, yoksa beklemeli mi?
Wall Street analistlerine göre, 3 analist BioSyent Inc. için analist derecelendirmeleri gerçekleştirdi, bunlar 2 güçlü al, 4 al, 1 tut, 0 sat ve 2 güçlü sat içermektedir